Entrada Therapeutics' mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada's technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
12/18/18	$59,000,000	Series A	5AM Ventures Agent Capital MPM Capital MRL Ventures Fund Roche Venture Fund	undisclosed
03/31/21	$116,000,000	Series B	5AM Ventures CureDuchenne Ventures Goldman Sachs Moore Strategic Ventures MPM Capital MRL Ventures Fund Point72 Asset Management Qatar Investment Authority Redmile Group TCG Wellington Management Company	undisclosed